Background Deciding when to biopsy a man with non-suspicious DRE findings and tPSA in
the 4–10 ng/ml range can be challenging, because two-thirds of such biopsies are typically …

Background: The Prostate Health Index (phi) outperforms PSA and other PSA derivatives for
the diagnosis of prostate cancer (PCa). The impact of phi testing in the real-world clinical …

Purpose: We evaluated the ability of PHI to discriminate aggressive prostate cancer from
indolent or no cancer in a biopsy naïve population. Materials and Methods: Two …

Background The performance of prostate health index (phi) in predicting prostate biopsy
outcomes has been well established for patients with prostate‐specific antigen (PSA) values …

The prostate health index (phi) is a FDA-approved blood test combining total, free and−
2proPSA with greater specificity than free and total PSA for clinically-significant prostate …

Purpose: The Prostate Health Index (phi) is a new test combining total, free and [-2] proPSA
into a single score. It was recently approved by the FDA and is now commercially available …

Background Evidence regarding the diagnostic accuracy of a [-2] proPSA derivative, namely,
the prostate health index (PHI), to predict the presence of prostate cancer (PCa) in …

Objectives To explore the utility of Prostate Health Index (PHI) density for the detection of
clinically significant prostate cancer (PC a) in a contemporary cohort of men presenting for …

Background External validation of a prediction tool is mandatory to assess the tool's
accuracy and generalizability within different patient cohorts. Objective To externally validate …

BACKGROUND It remains unclear whether the Prostate Health Index (PHI) or the urinary
Prostate‐Cancer Antigen 3 (PCA‐3) score is more accurate at screening for prostate cancer …